The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
NeoImmuneTech
Neonc Technologies, Inc.
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
VM Oncology, LLC
Amgen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Seagen Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Sellas Life Sciences Group
Salubris Biotherapeutics Inc
Evopoint Biosciences Inc.
Fate Therapeutics
Xencor, Inc.
Merck Sharp & Dohme LLC
Aeglea Biotherapeutics
MultiVir, Inc.
Incyte Corporation